A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Inclusion Criteria: * A histologically or pathologically confirmed diagnosis of AML based on WHO classification with or without extramedullary disease except for central nervous system disease. * ECOG performance status ≤ 2 * Left ventricular ejection fraction (LVEF) ≥ 50% * Female patients of childbearing potential must have a negative pregnancy test \< 1 week prior to enrollment. * Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria: * Patients receiving any other investigational agents or immunotherapy * Patients who have received prior chemotherapy for AML with the exception of hydroxyurea or leukapheresis for leukocytosis; prior hypomethylating or immunomodulatory agents for MDS are allowed * Previous allo-HSCT of any kind * Active, uncontrolled infection including known hepatitis B or C * Active autoimmune disease and chronic inflammatory conditions requiring concurrent use of any systemic immunosuppressants or steroids. * History of any other active cancer diagnosis * Pregnant women * Known HIV-infected patients